论文部分内容阅读
目的:探讨胰岛素抵抗与非胰岛素抵抗多囊卵巢综合征的临床治疗对比。方法:共纳入100例多囊卵巢综合征患者,根据是否有胰岛素抵抗分为两组,A组为非胰岛素抵抗组给予常规治疗措施;B组为胰岛素抵抗组在给予常规治疗的基础上给予二甲双胍(0.5,bid,po)治疗。观察两组患者的体质指数(BMI)、血脂水平及性激素水平变化。结果:与A组(非胰岛素抵抗组)患者相比,B组(胰岛素抵抗组)患者的LH水平明显比较低,差异有统计学意义(P<0.05),而FSH及E2水平比较差异无统计学意义(P>0.05)。治疗后两组间血脂及体质指数比较结果显示:与A组(非胰岛素抵抗组)患者相比,B组(胰岛素抵抗组)患者的TG、HDL-C及BMI比较差异有统计学意义(P<0.05),而TC及LDL-C差异比较无统计学意义(P>0.05)。结论:两组PCOS患者性激素、血脂水平存在差异,非胰岛素抵抗患者LH水平升高明显,而胰岛素抵抗患者更容易出现血脂代谢的异常,因此临床上对有胰岛素抵抗的PCOS患者,需要积极改善胰岛素抵抗状态,减少相关并发症的发生。
Objective: To investigate the clinical treatment of insulin resistance and non-insulin resistance polycystic ovary syndrome. Methods: A total of 100 patients with polycystic ovary syndrome were enrolled. Patients in non-insulin resistance group were given routine treatment according to whether there was insulin resistance or not, while in insulin resistance group B, metformin was given on the basis of routine treatment (0.5, bid, po) treatment. Body mass index (BMI), blood lipid levels and sex hormone levels were observed in two groups. Results: Compared with patients in group A (non-insulin resistance group), the level of LH in group B (insulin resistance group) was significantly lower (P <0.05), while there was no statistical difference in FSH and E2 Significance (P> 0.05). The results of blood lipid and body mass index after treatment showed that there was significant difference of TG, HDL-C and BMI in group B (insulin resistance group) compared with group A (non-insulin resistance group) (P <0.05), but there was no significant difference between TC and LDL-C (P> 0.05). Conclusion: There is difference in the levels of sex hormones and blood lipids in two groups of patients with PCOS, LH levels in non-insulin resistance patients increased significantly, and insulin resistance patients are more prone to abnormal lipid metabolism, so clinical PCOS patients with insulin resistance, need to actively improve insulin Resist the state, reduce the occurrence of related complications.